Ultragenyx Pharmaceutical-Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates

Ultragenyx (RARE) came out with a quarterly loss of $1.39 per share versus the Zacks Consensus Estimate of a loss of$ 1.24. This compares to loss of $1.52 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.10%. A quarter ago, it was expected that this biotechnology company would post a loss of$ 1.45 per share when it actually produced a loss of $1.40, delivering a surprise of 3.45%.Over the last four quarters, the company has ...